On July 8, 2025, ZyVersa Therapeutics, Inc. entered into an agreement to induce the exercise of warrants at a reduced price of $0.67 per share, potentially raising $2.05 million for working capital. Additionally, they will issue new warrants equivalent to 200% of exercised shares, subject to stockholder approval.